• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

ConcertAI & NeoGenomics Launch CTO-H for Hematology Research

by Syed Hamza Sohail 12/05/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.

– CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collaboration jointly announced on Jan. 8, 2024, and the more recent joint research completed and scheduled for presentation at the 2024 American Society of Hematology Meeting on Monday, Dec. 9, in San Diego.

NeoGenomics and ConcertAI Introduce CTO-H: Transforming Hematological Malignancy Research

In 2023, NeoGenomics and ConcertAI collaborated to redefine research solutions for healthcare providers and biopharmaceutical companies addressing the rising number of new therapeutic entities targeting hematological malignancies. Their efforts culminated in the creation of CTO-H, a robust database comprising:

  • Over 370,000 patient lives with detailed clinical attributes.
  • 7 to 11 years of patient journey surveillance data.
  • Comprehensive biomarker insights, ranging from routine tests to advanced genetic variants.

Believed to be the largest reference dataset for hematological malignancies, CTO-H addresses critical challenges in hematological research. These include:

  • Defining representative populations for early-phase clinical trials.
  • Ensuring control groups align with the evolving treatment paradigms.
  • Navigating complexities in late-phase trials, including competing studies and recruitment within the targeted timeframe.

The treatment landscape for hematological malignancies has evolved significantly over the last five years, offering more effective options for patients. However, this progress has introduced challenges in clinical research, including heterogeneity in standard care, prolonged treatment durations, and increasingly complex measures of response and residual disease.

“CTO-H represents a pivotal achievement in advancing clinical analysis, study design, and execution planning for hematological malignancies,” said Jeff Elton, PhD, founding CEO of ConcertAI. “Its multi-modal solution delivers unparalleled depth in addressing the complexities of this research domain.”

Under this collaboration:

  • ConcertAI will deploy CTO-H through its CARAai™ cloud as a SaaS solution.
  • NeoGenomics will provide biomarker interpretation, specialized testing services, and expert clinical support to ensure high-confidence analyses and study designs.

Currently available as a pre-release solution, CTO-H will become widely available on January 17, 2025, promising to elevate the precision and efficiency of hematological research.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |